Rather, as HMBA and JQ1 synergize with other MEK inhibitors (Figure 2(d-f)) – which were not p-gp inhibitors (Supplemental Figure 3(a-b)) – and also with the ERK inhibitor SCH772984 (Figure 3(e-g)), suggests that the MAPK pathway maintains the viability of BETi-treated C6 glioma cells. The gene discussed is MAP2K7; the disease is central nervous system cancer.